VRTX Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX from our risk checks.
Narratives
BetaNarratives bring a range of perspectives from our community.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$418.82 |
| 52 Week High | US$448.40 |
| 52 Week Low | US$320.01 |
| Beta | 0.37 |
| 1 Month Change | 3.61% |
| 3 Month Change | -1.00% |
| 1 Year Change | 19.65% |
| 3 Year Change | 96.93% |
| 5 Year Change | 150.97% |
| Change since IPO | 9,207.11% |
Recent News & Updates
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Recent updates
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Shareholder Returns
| VRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 1.3% | 3.3% |
| 1Y | 19.6% | 3.0% | 25.0% |
Return vs Industry: VRTX exceeded the US Biotechs industry which returned 3% over the past year.
Return vs Market: VRTX underperformed the US Market which returned 25% over the past year.
Price Volatility
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 2.4% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: VRTX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VRTX fundamental statistics | |
|---|---|
| Market cap | US$105.86b |
| Earnings (TTM) | US$4.02b |
| Revenue (TTM) | US$10.19b |
26.9x
P/E Ratio10.6x
P/S RatioIs VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRTX income statement (TTM) | |
|---|---|
| Revenue | US$10.19b |
| Cost of Revenue | US$4.55b |
| Gross Profit | US$5.64b |
| Other Expenses | US$1.62b |
| Earnings | US$4.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.58 |
| Gross Margin | 55.35% |
| Net Profit Margin | 39.46% |
| Debt/Equity Ratio | 0% |
How did VRTX perform over the long term?
See historical performance and comparison